Head of BioProcess Development
David joined Tessera in 2021 as the Head of BioProcess Development. He leads a team of scientists and engineers for the process development, material production and analytical analysis of DNA, RNA, LNP, AAV.
David has over 25 years of bioprocess development for a range therapeutics including novel mAbs, peptides, anti infectives, biocatalysts and more recently cell and gene therapies. During his career at Merck & Co. Inc, David led early and late stage CMC teams, providing contributions to multiple IND's & BLA's for Biologics & Vaccines. David also led an innovation team that co-developed the state-of-the-art ambr250 high throughput bioreactor system and also pioneered ‘lights out’ automated continuous mAb production. More recently David pursued processing for personalized neoantigen T cell therapies and helped create corporate research for the technology provider Sartorius. David is helping Tessera drive digital workflows and high throughput automation to accelerate sustainable gene therapy process development.